Science Journal of Public Health
Volume 7, Issue 1, January 2019, Pages: 5-9
Received: Jan. 31, 2019;
Published: Feb. 1, 2019
Views 24 Downloads 9
Mengyu Li, Department of Breast Surgery, Binzhou People's Hospital, Binzhou City, P. R. China
Haiyan Wang, Department of Breast Surgery, Binzhou People's Hospital, Binzhou City, P. R. China
Haixia Zhao, Department of Breast Surgery, Binzhou People's Hospital, Binzhou City, P. R. China
Rui Zhang, Technical Office, People's Court of Bincheng District, Binzhou City, P. R. China
Wenjing Du, Technical Office, Binzhou Intermediate People's Court, Binzhou City, P. R. China
Objective: To explore the expressions of FHIT (Human fragile histidine triad), BCRP (breast cancer resistance protein) and Bcl-2 proteins in breast invasive ductal carcinoma (IDC) and its relationship with clinical pathological factors. Methods: The expressions of FHIT, BCRP and Bcl-2 proteins in 84 cases of intraoperative resection of primary breast IDC and 36 cases of normal breast tissue about 3 cm away from the neoplastci foci were detected with the method of immunohistochemical streptavidin-peroxidase (SP) to analyze the relationship between the three proteins and the pathological features of breast IDC. Results: The positive expression rates of FHIT, of BCRP and Bcl-2 were 42.86%, 72.62% and 61.90% respectively in the breast IDC group and 72.22%, 36.11% and 38.89 % respectively in the normal breast tissue control group, between which the differences were statistically significant (P <0.05). In the IDC group, the expression of the three proteins was related to the lymph nodes metastasis and tumor recurrence of breast IDC, but was not significantly correlated with the expression of estrogen receptor (ER), progesterone receptor (PR) and proto-oncogene human epidermal growth factor receptor 2 (Her-2). The expression of FHIT was negatively correlated with the expression of and Bcl-2 (r = -0.322, -0.389), but BCRP and Bcl-2 expression were positively correlated (r = 0.276). Conclusion: The abnormal expressions of FHIT, BCRP and Bcl-2 proteins in breast IDC may play an important role in its onset and development.
Expressions of FHIT, BCRP and Bcl-2 Proteins in Breast Invasive Ductal Carcinoma, Science Journal of Public Health.
Vol. 7, No. 1,
2019, pp. 5-9.
Ismail HM, Medhat AM, et al. Multiple Patterns of FHIT Gene Homozygous Deletion in Egyptian Breast Cancer Patients. Int J Breast Cancer, 2017, 45(18): 947-52.
Van A, Naaijkens BA, et al. The multidrug resistance protein breast cancer resistance protein (BCRP) protects adipose-derived stem cells against ischemic damage. Cell Biol Toxicol, 2016, 28(5): 303-15.
Wu B, Jiang W, et al. A New Strategy to Rapidly Evaluate Kinetics of Glucuronide Efflux by Breast Cancer Resistance Protein (BCRP/ABCG2). Pharm Res, 2017, 29(11): 3199-208.
Wang Y, Wang X, et al. Clusterin confers resistance to TNF-alpha-induced apoptosis in breast cancer cells through NF-kappaB activation and Bcl-2 overexpression. J Chemother, 2018, 24(6): 348-57.
Ismail HM, Medhat AM, et al. FHIT gene and flanking region on chromosome 3p are subjected to extensive allelic loss in Egyptian breast cancer patients. Mol Carcinog, 2017, 50(8): 625-34.
Syeed N, Husain SA, et al. Mutational and promoter hypermethylation status of FHIT gene in breast cancer patients of Kashmir. 2016, 707(2): 1-8.
Silva EW, Santos SC, et al. Concomitant loss of heterozygosity at the BRCA1 and FHIT genes as a prognostic factor in sporadic breast cancer. Cancer Genet Cytogenet, 2017, 199(1): 24-30.
Raish M, Dhillon VS, et al. Promoter Hypermethylation in Tumor Suppressing Genes p16 and FHIT and Their Relationship with Estrogen Receptor and Progesterone Receptor Status in Breast Cancer Patients from Northern India. Transl Oncol, 2016, 2(4): 264-70.
Naqvi RA, Hussain A, et al. Specific 50'CpG island methylation signatures of FHIT and p16 genes and their potential diagnostic relevance in Indian breast cancer patients. DNA Cell Biol, 2017, 27(9): 517-25.
Dankers AC, Sweep FC, et al. Localization of breast cancer resistance protein (Bcrp) in endocrine organs and inhibition of its transport activity by steroid hormones. Cell Tissue Res, 2017, 349(2): 551-63.
Agarwal S, Uchida Y, et al. Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice. Drug Metab Dispos, 2017, 40(6): 1164-9.
Bhatia P, Bernier M. Breast cancer resistance protein (BCRP/ABCG2) localises to the nucleus in glioblastoma multiforme cells. Xenobiotica, 2018, 42(8): 748-55.
Hamdan AM, Koyanagi S, et al. Intestinal expression of mouse Abcg2/breast cancer resistance protein (BCRP) gene is under control of circadian clock-activating transcription factor-4 pathway. J Biol Chem, 2017, 287(21): 17224-31.
Chappell WH, Abrams SL, et al. Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine. Cell Cycle, 2016, 11(23):542-8.
Mao H, Gu H, et al. Involvement of the mitochondrial pathway and Bim/Bcl-2 balance in dihydroartemisinin-induced apoptosis in human breast cancer in vitro. Int J Mol Med, 2017, 31(1): 213-8.
Jaafar H, Abdullah S. Expression of Bax and Bcl-2 in Tumour Cells and Blood Vessels of Breast Cancer and their Association with Angiogenesis and Hormonal Receptors. Asian Pac J Cancer Prev, 2017, 13(8): 3857-62.
Rajah TT, Peine KJ, et al. Physiological concentrations of genistein and 17beta-estradiol inhibit MDA-MB-231 breast cancer cell growth by increasing BAX/BCL-2 and reducing pERK1/2. Anticancer Res, 2017, 32(4): 1181-91.
Larsen MS, Bjerre K. Prognostic value of Bcl-2 in two independent populations of estrogen receptor positive breast cancer patients treated with adjuvant endocrine therapy. Acta Oncol, 2016, 51(6): 781-9.
Duo J, Ying GG. Quercetin inhibits human breast cancer cell proliferation and induces apoptosis via Bcl-2 and Bax regulation. Mol Med Report, 2017, 5(6): 1453-6.